{"nctId":"NCT02252016","briefTitle":"Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)","startDateStruct":{"date":"2014-10-22","type":"ACTUAL"},"conditions":["Hepatitis C"],"count":159,"armGroups":[{"label":"Immediate Treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Grazoprevir + Elbasvir"]},{"label":"Deferred Treatment","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Grazoprevir + Elbasvir","Drug: Placebo"]}],"interventions":[{"name":"Grazoprevir + Elbasvir","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* has HCV GT1, GT4, or GT6 with sickle cell anemia, thalassemia, or hemophilia/von Willebrand disease\n* has cirrhosis or is non-cirrhotic\n* is human immunodeficiency virus (HIV) coinfected or not infected with HIV\n* is a female of non childbearing potential, or is male or female and uses an acceptable method(s) of contraception\n\nExclusion Criteria:\n\n* has evidence of decompensated liver disease\n* is coinfected with hepatitis B\n* has had a malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n* has hepatocellular carcinoma (HCC) or is under evaluation for HCC\n* has clinically-relevant drug or alcohol abuse within 12 months of screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)","description":"The percentage of participants in the both arms achieving SVR12 (i.e., HCV riboncleic acid \\[RNA\\] level below the lower limit of quantification \\[LLoQ\\] 12 weeks after completing study therapy) was determined. HCV RNA levels were measured using the Roche COBAS™ Taqman™ HCV Test v2.0 (High Pure System), which has a LLoQ of \\<15 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null},{"groupId":"OG001","value":"91.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Experiencing an Adverse Event (AE)","description":"An AE is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.9","spread":null},{"groupId":"OG001","value":"65.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Discontinuing From Study Treatment Due to an AE(s)","description":"An AE is any untoward medical occurrence which does not necessarily have to have a causal relationship with this treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)","description":"The percentage of participants in both arms achieving SVR24 (i.e., HCV RNA level below the LLoQ 24 weeks after completing study therapy) was determined. HCV RNA levels were measured using the Roche COBAS™ Taqman™ HCV Test v2.0 (High Pure System), which has a LLoQ of \\<15 IU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.7","spread":null},{"groupId":"OG001","value":"91.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":107},"commonTop":["Headache","Fatigue","Nausea","Asthenia","Arthralgia"]}}}